SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Felix B who wrote (3223)1/27/2021 6:33:11 AM
From: Biotechwantabe  Read Replies (1) | Respond to of 3557
 
COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection

This trial shows that they are trying to use Sc for outpatients. I don’t see any reason why Sc won’t be used for all patients.



To: Felix B who wrote (3223)1/27/2021 6:53:59 AM
From: Biotechwantabe  Respond to of 3557
 
Those numbers you linked are for allocation correct? Yes. Is there for actual patient treated? Not that I can find. But the amounts allocated are pretty small right now. Can’t imagine states not going through supply quickly.

Really we should only care how much delivered from regeneron to feds. As that will be how regeneron gets paid.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News